51����

Bio

Dr. Miranda Perry is a former senior postdoctoral fellow at the 51����. She was born in Florida in 1982 and received her degrees in Chemistry from the University of West Florida in 2004 (B.Sc.) and the University of South Florida in 2009 (Ph.D.). Her graduate work, supervised by Prof. Mike Zaworotko, addressed the supramolecular assembly of cocrystals and their role in solid-state synthesis. From 2009 to 2014 she worked as a research scientist at Thar Pharmaceuticals where her work involved the development of novel crystal forms of pharmaceuticals, specifically cocrystals, salts, and polymorphs. She is the co-author of nine peer-reviewed publications, co-inventor on several patent applications, and has presented her work at numerous regional, national, and international conferences. Current research interests include developing novel multi-component pharmaceutical materials (MPMs) via a crystal engineering based approach. Specific areas of focus include cocrystallization of pharmaceuticals and ionic compounds.

Publications

Bibliometrics: h-index: 12

1. Bajpai, A.; Scott, H.S.; Chen, K-J.; Lusi, M.; Perry, M.L.; Pham, T.; Space, B.; Zaworotko, M.J. “Towards an Understanding of the Propensity of Crystalline Hydrate Formation by Molecular Compounds”, IUCrJ, 2016, 3 (6), 430-439. Times cited: 0.

2. Golob, S.; Perry, M.L.; Lusi, M.; Chierotti, M.R.; Grabnar, I.; Voinovich, D.; Zaworotko, M.J. “Improving biopharmaceutical properties of Vinpocetine through cocrystallization”, J.Pharm.Sci., 2016, 105 (12), 3626-3633.Times cited: 0.

3. O’Nolan, D.; Perry, M.L.; Zaworotko, M.J. “Chloral Hydrate Polymorphs and Cocrystals Revisited: Solving two Pharmaceutical Cold Cases” Cryst. Growth & Des., 2016, 16 (4), 2211-2217. Times cited: 1.

4. Duggirala, N.K.; Perry, M.L.; Almarsson, Ö.; Zaworotko, M.J. “Pharmaceutical cocrystals: along the path to improved medicines”, Chem. Commun., 2016, 52, 640-655. Times cited: 63.

5. Duggirala, N.K.; Wood, G.P.F.; Fischer, A.; Wojtas, L.; Perry, M.L.; Zaworotko, M.J, “Hydrogen Bond Hierarchy: Persistent Phenol···Chloride Hydrogen Bonds in the Presence of Carboxylic Acid Moieties”, Cryst. Growth & Des.,2015, 15, 4341-4354. Times cited: 15.

6. Shan, N.; Perry, M.L.; Weyna, D.R.; Zaworotko, M.J., “Impact of pharmaceutical cocrystals: the effects on drug pharmacokinetics”, Expert Opin. Drug Metab. & Toxicol., 2014, 10, 9, 1255-1271. Times cited: 29.

7. Aitipamula, S.; Banerjee, R.; Cheney, M.L.; Zaworotko, M.J., et. al., “Polymorphs, Salts, and Cocrystals: What’s in a Name?”, Cryst. Growth & Des., 2012, 12, 2147-2152. Times cited: 198.

8. Weyna, D.R.; Cheney, M.L.; Shan, N.; Hanna, M.; Wojtas, L.; Zaworotko, M.J.; Sava, V.; Song, S.; Sanchez-Ramos, J.R; “Improving Solubility and Pharmacokinetics of Meloxicam via Multiple-Component Crystal Formation”,Mol. Pharmaceutics., 2012, 9,  2094-2102. Times cited: 36.

9. Weyna, D.R.; Cheney, M.L.; Shan, N.; Hanna, M.; Wojtas, L.; Zaworotko, M.J.; “Crystal Engineering of multiple-component organic solids: Pharmaceutical cocrystals of tadalafil with persistent hydrogen bonding motifs”, Cryst. Eng. Comm., 2012, 14, 2377-2380. Times cited: 20.

10. Cheney, M.L.; Weyna, D.R.; Shan, N.; Hanna, M.; Wojtas, L.; Zaworotko, M.J.; “Coformer Selection in Pharmaceutical Cocrystal Development: A Case Study of a Meloxicam Aspirin Cocrystal that Exhibits Enhanced Solubility and Pharmacokinetics”, J. Pharm. Sci, 2011,100, 2172-2181. Times cited: 79.

11. Vetromile, C.M.; Perman, J.; Cheney, M.L.; Zaworotko, M.J.; Larsen, R.W.; “Excited State Properties of 9-Amino Acridine Surface Adsorbed onto αZr-phosphate particles”, Spectrochim Acta A Mol Biomol Spectrosc., 2011, 78, 648-652. Times cited: 3.

12. Cheney, M.L.; Weyna, D.R.; Shan, N.; Hanna, M.; Wojtas, L.; Zaworotko, M.J.; “Supramolecular Architectures of Meloxicam Carboxylic acid Cocrystals, a Crystal Engineering Case Study”, Cryst. Growth Des., 2010, 10, 4401-4413. Times cited: 67.

13. Cheney, M.L.; Shan, N.; Healey, E.H.; Hanna, M.H.; Wojtas, L.; Zaworotko, M.J.; Sava, V.; Song, S.; Sanchez-Ramos, J.R., “Effects of Crystal Form on Solubility and Pharmacokinetics: A Crystal Engineering Case Study of Lamotrigine”, Cryst. Growth Des., 2010, 10, 394-405. Times cited: 151.

14. Cheney, M. L.; Beaton, S.; Zaworotko, M. J.; Singer, R. D., “Cocrystal Controlled Solid-State Synthesis – A Green Chemistry Experiment for 51���� Organic Chemistry”, J. Chem. Ed., 2008, 85, 1649-1651. Times cited: 17.

15. Cheney, M.L.; McManus, G. J.; Perman, J. A.; Wang, Z.; Zaworotko, M.J., “The Role of Cocrystals in Solid-State Synthesis: Cocrystal-Controlled Solid-State Synthesis”, Cryst. Growth Des., 2007, 7, 616-617. Times cited: 57.